{"id":49001,"date":"2025-11-26T21:06:22","date_gmt":"2025-11-26T13:06:22","guid":{"rendered":"https:\/\/flcube.com\/?p=49001"},"modified":"2025-11-26T21:06:25","modified_gmt":"2025-11-26T13:06:25","slug":"cms-ira-drug-pricing-round-2-delivers-62-average-cut-ozempic-falls-71","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49001","title":{"rendered":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%"},"content":{"rendered":"\n<p>The <strong>U.S. Centers for Medicare &amp; Medicaid Services (CMS)<\/strong> announced results of the second round of prescription drug price negotiations under the <strong>Inflation Reduction Act (IRA)<\/strong>, with <strong>15 drugs<\/strong> securing an <strong>average 62% price reduction<\/strong> and a <strong>maximum cut of 85%<\/strong>, delivering projected taxpayer savings of <strong>$12\u202fbillion<\/strong> and <strong>$685\u202fmillion<\/strong> in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-negotiation-results-summary\">Negotiation Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Brand Name<\/th><th>Company<\/th><th>30\u2011Day Cost (USD)<\/th><th>Original Price (USD)<\/th><th>Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>Ozempic\/Rybelsus\/Wegovy<\/strong> (semaglutide)<\/td><td>Novo Nordisk<\/td><td><strong>274<\/strong><\/td><td>959<\/td><td><strong>\u201171%<\/strong><\/td><\/tr><tr><td><strong>Trelegy Ellipta<\/strong> (fluticasone\/umeclidinium\/vilanterol)<\/td><td>GSK<\/td><td><strong>175<\/strong><\/td><td>654<\/td><td><strong>\u201173%<\/strong><\/td><\/tr><tr><td><strong>Xtandi<\/strong> (enzalutamide)<\/td><td>Astellas<\/td><td><strong>7,004<\/strong><\/td><td>13,480<\/td><td><strong>\u201148%<\/strong><\/td><\/tr><tr><td><strong>Pomalyst<\/strong> (pomalidomide)<\/td><td>Bristol\u2011Myers Squibb<\/td><td><strong>8,650<\/strong><\/td><td>21,744<\/td><td><strong>\u201160%<\/strong><\/td><\/tr><tr><td><strong>Ofev<\/strong> (nintedanib)<\/td><td>Boehringer Ingelheim<\/td><td><strong>6,350<\/strong><\/td><td>12,622<\/td><td><strong>\u201150%<\/strong><\/td><\/tr><tr><td><strong>Ibrance<\/strong> (palbociclib)<\/td><td>Pfizer<\/td><td><strong>7,871<\/strong><\/td><td>15,741<\/td><td><strong>\u201150%<\/strong><\/td><\/tr><tr><td><strong>Linzess<\/strong> (linaclotide)<\/td><td>AbbVie<\/td><td><strong>136<\/strong><\/td><td>539<\/td><td><strong>\u201175%<\/strong><\/td><\/tr><tr><td><strong>Calquence<\/strong> (acalabrutinib)<\/td><td>AstraZeneca<\/td><td><strong>8,600<\/strong><\/td><td>14,228<\/td><td><strong>\u201140%<\/strong><\/td><\/tr><tr><td><strong>Austedo\/Austedo XR<\/strong> (deutetrabenazine)<\/td><td>Teva<\/td><td><strong>4,093<\/strong><\/td><td>6,623<\/td><td><strong>\u201138%<\/strong><\/td><\/tr><tr><td><strong>Breo Ellipta<\/strong> (fluticasone\/vilanterol)<\/td><td>GSK<\/td><td><strong>67<\/strong><\/td><td>397<\/td><td><strong>\u201183%<\/strong><\/td><\/tr><tr><td><strong>Xifaxan<\/strong> (rifaximin)<\/td><td>Salix Pharma<\/td><td><strong>1,000<\/strong><\/td><td>2,696<\/td><td><strong>\u201163%<\/strong><\/td><\/tr><tr><td><strong>Vraylar<\/strong> (cariprazine)<\/td><td>AbbVie<\/td><td><strong>770<\/strong><\/td><td>1,376<\/td><td><strong>\u201144%<\/strong><\/td><\/tr><tr><td><strong>Tradjenta<\/strong> (linagliptin)<\/td><td>Boehringer Ingelheim<\/td><td><strong>78<\/strong><\/td><td>488<\/td><td><strong>\u201184%<\/strong><\/td><\/tr><tr><td><strong>Janumet\/Janumet XR<\/strong> (sitagliptin\/metformin)<\/td><td>Merck<\/td><td><strong>80<\/strong><\/td><td>526<\/td><td><strong>\u201185%<\/strong><\/td><\/tr><tr><td><strong>Otezla<\/strong> (apremilast)<\/td><td>Amgen<\/td><td><strong>1,650<\/strong><\/td><td>4,722<\/td><td><strong>\u201165%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-context-amp-market-impact\">Program Context &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Historical Precedent:<\/strong> The first IRA negotiation round in <strong>August\u202f2024<\/strong> covered <strong>10 drugs<\/strong> with <strong>38\u201179%<\/strong> price cuts, effective <strong>2026<\/strong>; this second round expands scope and average discount depth<\/li>\n\n\n\n<li><strong>Pharma Revenue at Risk:<\/strong> The 15 drugs generated <strong>$45\u202fbillion<\/strong> in Medicare spending in 2024; the new pricing reduces manufacturer revenue by an estimated <strong>$28\u202fbillion<\/strong> annually when fully implemented<\/li>\n\n\n\n<li><strong>Stock Reactions:<\/strong> <strong>Novo Nordisk<\/strong> fell <strong>5.1%<\/strong> on Ozempic\u2019s 71% cut; <strong>GSK<\/strong> declined <strong>3.2%<\/strong>; <strong>AbbVie<\/strong> dropped <strong>4.0%<\/strong> on combined Linzess\/Vraylar exposure; <strong>Merck<\/strong> slid <strong>2.8%<\/strong> despite Janumet\u2019s 85% reduction being largely anticipated<\/li>\n\n\n\n<li><strong>Taxpayer Savings:<\/strong> CMS projects <strong>$12\u202fbillion<\/strong> in Medicare savings in 2027 alone, rising to <strong>$85\u202fbillion<\/strong> over the first decade of the program<\/li>\n\n\n\n<li><strong>Patient Impact:<\/strong> <strong>7.2\u202fmillion<\/strong> Medicare beneficiaries will see average out\u2011of\u2011pocket reductions of <strong>$95 per 30\u2011day prescription<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-implications\">Industry Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Impact<\/th><th>2027+ Outlook<\/th><\/tr><\/thead><tbody><tr><td><strong>Medicare Drug Spending<\/strong><\/td><td>Flat vs. 2024<\/td><td><strong>\u201115%<\/strong> CAGR through 2030<\/td><\/tr><tr><td><strong>Pharma R&amp;D Budgets<\/strong><\/td><td><strong>\u20112\u20113%<\/strong> reallocation from price\u2011pressured areas<\/td><td>Increased focus on rare disease\/orphan drugs<\/td><\/tr><tr><td><strong>IRA Litigation<\/strong><\/td><td>Industry appeals ongoing<\/td><td>Supreme Court review likely in 2026<\/td><\/tr><tr><td><strong>Private Payer Spillover<\/strong><\/td><td>Minimal in 2025<\/td><td><strong>30\u201140%<\/strong> of commercial plans adopting reference pricing by 2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Strategy:<\/strong> Manufacturers are accelerating <strong>value\u2011based contracts<\/strong> and <strong>indication\u2011specific pricing<\/strong> to mitigate IRA impact<\/li>\n\n\n\n<li><strong>Pipeline Shift:<\/strong> Companies like <strong>Pfizer<\/strong> and <strong>BMS<\/strong> have already announced <strong>30% cuts<\/strong> in primary care R&amp;D, redirecting investment to <strong>oncology and rare disease<\/strong> where IRA negotiation risks are lower<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CMS drug price negotiation impacts, pharmaceutical industry revenue effects, and Medicare savings projections. Actual results may differ materially due to legal challenges, policy changes, and varying manufacturer compliance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Centers for Medicare &amp; Medicaid Services (CMS) announced results of the second round&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49068,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[],"class_list":["post-49001","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Centers for Medicare &amp; Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49001\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%\" \/>\n<meta property=\"og:description\" content=\"The U.S. Centers for Medicare &amp; Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49001\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T13:06:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T13:06:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%\",\"datePublished\":\"2025-11-26T13:06:22+00:00\",\"dateModified\":\"2025-11-26T13:06:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601-1.webp\",\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49001#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49001\",\"name\":\"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601-1.webp\",\"datePublished\":\"2025-11-26T13:06:22+00:00\",\"dateModified\":\"2025-11-26T13:06:25+00:00\",\"description\":\"The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49001\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49001#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71% - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49001","og_locale":"en_US","og_type":"article","og_title":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%","og_description":"The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.","og_url":"https:\/\/flcube.com\/?p=49001","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T13:06:22+00:00","article_modified_time":"2025-11-26T13:06:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49001#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49001"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%","datePublished":"2025-11-26T13:06:22+00:00","dateModified":"2025-11-26T13:06:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49001"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49001#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49001#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49001","url":"https:\/\/flcube.com\/?p=49001","name":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49001#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49001#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","datePublished":"2025-11-26T13:06:22+00:00","dateModified":"2025-11-26T13:06:25+00:00","description":"The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round of prescription drug price negotiations under the Inflation Reduction Act (IRA), with 15 drugs securing an average 62% price reduction and a maximum cut of 85%, delivering projected taxpayer savings of $12\u202fbillion and $685\u202fmillion in out\u2011of\u2011pocket savings for Medicare enrollees in 2027.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49001#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49001"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49001#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","width":1080,"height":608,"caption":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49001#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49001"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49001\/revisions"}],"predecessor-version":[{"id":49067,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49001\/revisions\/49067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49068"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}